<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621187</url>
  </required_header>
  <id_info>
    <org_study_id>TA117</org_study_id>
    <nct_id>NCT05621187</nct_id>
  </id_info>
  <brief_title>Post Market Clinical Follow-up Study for the Pamira ICD Lead Family</brief_title>
  <official_title>BIO|MASTER.Pamira Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Confirm clinical safety and performance of the Pamira lead to support the regulatory post&#xD;
      market strategy in Europe and other regions and validating promotional claims by&#xD;
&#xD;
        -  demonstrating clinical safety&#xD;
&#xD;
        -  evaluating performance based on sensing and pacing assessment&#xD;
&#xD;
        -  collecting additional data of interest to assess other aspects such as the handling and&#xD;
           usability&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2022</start_date>
  <completion_date type="Anticipated">February 28, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pamira lead related SADE-d free rate at 6 months after implantation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1a and b: Pamira lead related SADE-d free rate at 3 and 12 months after implantation</measure>
    <time_frame>3 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2a and 2b: Rate of appropriate right ventricular sensing at the 6- and 12-month follow-up</measure>
    <time_frame>6 months, 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3a and 3b: Rate of appropriate right ventricular pacing at the 6- and 12-month follow-up</measure>
    <time_frame>6 months, 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Heart Failure</condition>
  <condition>Tachyarrhythmia</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pamira ICD lead family</intervention_name>
    <description>Implantation, measurements and follow-up schedule</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Standard indication for ICD or CRT-D therapy according to clinical guidelines&#xD;
&#xD;
          -  Planned for de novo implantation of a BIOTRONIK ICD or CRT-D in combination with&#xD;
             Pamira&#xD;
&#xD;
          -  Ability to understand the nature of the study and willingness to provide written&#xD;
             informed consent&#xD;
&#xD;
          -  Ability and willingness to perform all follow-up visits at the study site&#xD;
&#xD;
          -  Ability and willingness to use the CardioMessenger and acceptance the BIOTRONIK Home&#xD;
             Monitoring® concept&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mechanical tricuspid valve prosthesis or a severe tricuspid valve disease&#xD;
&#xD;
          -  Known Dexamethasone acetate intolerance&#xD;
&#xD;
          -  Cardiac surgical post-implantation procedure planned within 12 months (including&#xD;
             interventional procedures like ablation, valve replacement, heart transplant etc.)&#xD;
&#xD;
          -  Less than 18 years old&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Participating in another interventional clinical investigation&#xD;
&#xD;
          -  Life-expectancy less than 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Deneke, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RHÖN-KLINIKUM Campus Bad Neustadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja Viehrig, Dr.</last_name>
    <phone>+49 (0) 151 6890-1304</phone>
    <email>anja.viehrig@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ines Danzke</last_name>
    <phone>+49 (0) 151 6890-1352</phone>
    <email>ines.danzke@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <zip>NSW 2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Jackson, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>December 16, 2022</last_update_submitted>
  <last_update_submitted_qc>December 16, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

